SCI: Preventing Overweight (2007)
- To assess body composition of a group of SCI subjects several years after trauma
- To evaluate reliability of determining fat mass using skinfold thickness
- To investigate the relationship between injury duration and fat mass
For SCI subjects:
- Absence of cardiovascular diseases, diabetes, or hormonal pathologies
- Lesion duration of at least 4 years
For control subjects:
- Healthy
- Matched to SCI for age and body mass index
Recruitment
Methods not specified.
Design
Comparison of fat mass, fat free mass and bone mineral density by dual X-ray absorptiometry and skinfold measurements in 13 individuals with SCI and 13 healthy controls matched for age and BMI.
Blinding used (if applicable): Not applicable.
Intervention (if applicable): Not applicable.
Statistical Analysis
- Student's t test (comparisons between groups) for unpaired data
- Simple linear regression analysis for relationship between variables
Timing of Measurements
One time measurement.
Dependent Variables
- fat mass (FM) % measured or calculated by
- dual-energy X-ray absorptiometry (DXA) scanning (Lunar DPX-IQ, MEC, Minster OH)
- Durnin-Womersley equation from the value of four standard skinfolds (biceps, triceps, suprailiac, and subscapular) measured with a Holtain caliper (Crymych, UK).
- fat free mass (FFM)% by DXA (as above)
- bone mineral density (BMD)% by DXA (as above)
Independent Variables
- SCI
Control Variables
- age
- BMI
Initial N: 13 males with SCI (12 paraplegic, 1 tetraplegic); 13 healthy male controls
Attrition (final N): no attrition reported
Age: 33.8±5.4 yrs for SCI; 35.4±15.6 yrs for controls
Ethnicity: not reported
Other relevant demographics: none reported
Anthropometrics:
- weight: 84.0±15.0 kg for SCI; 76.8±9.9 for controls
- height: 181±6cm for SCI; 176±6 for controls
- BMI: 25.7±4.3 kg/m2 for SCI; 24.5±2.4 for controls
- WHR: 0.89±0.09 for SCI; 0.89±0.08 for controls
Location:
University of Milan, Italy
Table 1: Percentage of body weight of fat mass by two methods
Variables |
SCI group |
Control group
|
Statistical Significance of Group Difference |
Total body fat mass by DXA method (%) | 31.1±8.2*
|
20.8±6.9 | p<0.05 (control vs SCI) |
Total body fat mass by skinfold method (%) |
19.6±4.2* |
22.3±6.8 |
|
*by linear regression analysis, fat mass measured by skinfold method for SCI group was significantly lower than fat mass measured with DXA scanning (p<0.05)
Other Findings
- Percentage of fat free mass was significantly lower in trunk and lower limbs, and upper limb fat free mass was significantly higher in the SCI group than the control group
- No significant correlation was found between lesion duration and percentage of fat mass in the SCI group.
- Total body bone mineral density didn't differ between groups
University/Hospital: | University of Milan | ||
Not-for-profit |
|
- Results are not applicable generally as they do not include women, ethnic diversity, and tetraplegic subjects
- While subjects were age and BMI matched, other variables (ethnicity) were not matched
- Only one skinfold formula was tested
Quality Criteria Checklist: Primary Research
|
|||
Relevance Questions | |||
1. | Would implementing the studied intervention or procedure (if found successful) result in improved outcomes for the patients/clients/population group? (Not Applicable for some epidemiological studies) | ??? | |
2. | Did the authors study an outcome (dependent variable) or topic that the patients/clients/population group would care about? | Yes | |
3. | Is the focus of the intervention or procedure (independent variable) or topic of study a common issue of concern to dieteticspractice? | Yes | |
4. | Is the intervention or procedure feasible? (NA for some epidemiological studies) | Yes | |
Validity Questions | |||
1. | Was the research question clearly stated? | Yes | |
1.1. | Was (were) the specific intervention(s) or procedure(s) [independent variable(s)] identified? | Yes | |
1.2. | Was (were) the outcome(s) [dependent variable(s)] clearly indicated? | Yes | |
1.3. | Were the target population and setting specified? | Yes | |
2. | Was the selection of study subjects/patients free from bias? | ??? | |
2.1. | Were inclusion/exclusion criteria specified (e.g., risk, point in disease progression, diagnostic or prognosis criteria), and with sufficient detail and without omitting criteria critical to the study? | No | |
2.2. | Were criteria applied equally to all study groups? | Yes | |
2.3. | Were health, demographics, and other characteristics of subjects described? | No | |
2.4. | Were the subjects/patients a representative sample of the relevant population? | Yes | |
3. | Were study groups comparable? | Yes | |
3.1. | Was the method of assigning subjects/patients to groups described and unbiased? (Method of randomization identified if RCT) | N/A | |
3.2. | Were distribution of disease status, prognostic factors, and other factors (e.g., demographics) similar across study groups at baseline? | N/A | |
3.3. | Were concurrent controls or comparisons used? (Concurrent preferred over historical control or comparison groups.) | Yes | |
3.4. | If cohort study or cross-sectional study, were groups comparable on important confounding factors and/or were preexisting differences accounted for by using appropriate adjustments in statistical analysis? | N/A | |
3.5. | If case control study, were potential confounding factors comparable for cases and controls? (If case series or trial with subjects serving as own control, this criterion is not applicable.) | ??? | |
3.6. | If diagnostic test, was there an independent blind comparison with an appropriate reference standard (e.g., "gold standard")? | N/A | |
4. | Was method of handling withdrawals described? | N/A | |
4.1. | Were follow-up methods described and the same for all groups? | N/A | |
4.2. | Was the number, characteristics of withdrawals (i.e., dropouts, lost to follow up, attrition rate) and/or response rate (cross-sectional studies) described for each group? (Follow up goal for a strong study is 80%.) | N/A | |
4.3. | Were all enrolled subjects/patients (in the original sample) accounted for? | N/A | |
4.4. | Were reasons for withdrawals similar across groups? | N/A | |
4.5. | If diagnostic test, was decision to perform reference test not dependent on results of test under study? | N/A | |
5. | Was blinding used to prevent introduction of bias? | N/A | |
5.1. | In intervention study, were subjects, clinicians/practitioners, and investigators blinded to treatment group, as appropriate? | N/A | |
5.2. | Were data collectors blinded for outcomes assessment? (If outcome is measured using an objective test, such as a lab value, this criterion is assumed to be met.) | N/A | |
5.3. | In cohort study or cross-sectional study, were measurements of outcomes and risk factors blinded? | N/A | |
5.4. | In case control study, was case definition explicit and case ascertainment not influenced by exposure status? | N/A | |
5.5. | In diagnostic study, were test results blinded to patient history and other test results? | N/A | |
6. | Were intervention/therapeutic regimens/exposure factor or procedure and any comparison(s) described in detail? Were interveningfactors described? | Yes | |
6.1. | In RCT or other intervention trial, were protocols described for all regimens studied? | N/A | |
6.2. | In observational study, were interventions, study settings, and clinicians/provider described? | Yes | |
6.3. | Was the intensity and duration of the intervention or exposure factor sufficient to produce a meaningful effect? | Yes | |
6.4. | Was the amount of exposure and, if relevant, subject/patient compliance measured? | N/A | |
6.5. | Were co-interventions (e.g., ancillary treatments, other therapies) described? | N/A | |
6.6. | Were extra or unplanned treatments described? | N/A | |
6.7. | Was the information for 6.4, 6.5, and 6.6 assessed the same way for all groups? | N/A | |
6.8. | In diagnostic study, were details of test administration and replication sufficient? | Yes | |
7. | Were outcomes clearly defined and the measurements valid and reliable? | Yes | |
7.1. | Were primary and secondary endpoints described and relevant to the question? | Yes | |
7.2. | Were nutrition measures appropriate to question and outcomes of concern? | N/A | |
7.3. | Was the period of follow-up long enough for important outcome(s) to occur? | N/A | |
7.4. | Were the observations and measurements based on standard, valid, and reliable data collection instruments/tests/procedures? | Yes | |
7.5. | Was the measurement of effect at an appropriate level of precision? | Yes | |
7.6. | Were other factors accounted for (measured) that could affect outcomes? | ??? | |
7.7. | Were the measurements conducted consistently across groups? | Yes | |
8. | Was the statistical analysis appropriate for the study design and type of outcome indicators? | Yes | |
8.1. | Were statistical analyses adequately described and the results reported appropriately? | Yes | |
8.2. | Were correct statistical tests used and assumptions of test not violated? | Yes | |
8.3. | Were statistics reported with levels of significance and/or confidence intervals? | Yes | |
8.4. | Was "intent to treat" analysis of outcomes done (and as appropriate, was there an analysis of outcomes for those maximally exposed or a dose-response analysis)? | N/A | |
8.5. | Were adequate adjustments made for effects of confounding factors that might have affected the outcomes (e.g., multivariate analyses)? | N/A | |
8.6. | Was clinical significance as well as statistical significance reported? | Yes | |
8.7. | If negative findings, was a power calculation reported to address type 2 error? | N/A | |
9. | Are conclusions supported by results with biases and limitations taken into consideration? | Yes | |
9.1. | Is there a discussion of findings? | Yes | |
9.2. | Are biases and study limitations identified and discussed? | Yes | |
10. | Is bias due to study's funding or sponsorship unlikely? | Yes | |
10.1. | Were sources of funding and investigators' affiliations described? | ??? | |
10.2. | Was the study free from apparent conflict of interest? | Yes | |